Trials / Completed
CompletedNCT05995379
Donor Derived Cell-free DNA and Rejection of Kidney Allografts
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,500 (actual)
- Sponsor
- Paris Translational Research Center for Organ Transplantation · Academic / Other
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
To assess the association of dd-cfDNA with the presence, activity and severity of allograft rejection, and determine whether dd-cfDNA adds value to standard of care monitoring parameters in detecting kidney allograft rejection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Donor-derived cell-free DNA | Cell-free DNA (cfDNA) is fragmented extracellular DNA released in the bloodstream from cells undergoing apoptosis or necrosis. In transplantation, donor-derived cfDNA (dd-cfDNA) is detected in the blood of kidney recipients and has been proposed as a noninvasive biomarker to detect rejection. One additional blood sample will be collected and dd-cfDNA levels will be centrally analyzed. |
Timeline
- Start date
- 2011-09-21
- Primary completion
- 2022-08-09
- Completion
- 2022-08-09
- First posted
- 2023-08-16
- Last updated
- 2023-08-16
Source: ClinicalTrials.gov record NCT05995379. Inclusion in this directory is not an endorsement.